Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
4.27
USD
|
+1.43%
|
|
-10.86%
|
+1.67%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
759.3
|
194
|
390.3
|
482.9
|
-
|
-
|
Enterprise Value (EV)
1 |
516.2
|
37.56
|
390.3
|
482.9
|
482.9
|
482.9
|
P/E ratio
|
-3.94
x
|
-1.83
x
|
-3.5
x
|
-5.17
x
|
-6.01
x
|
-8.32
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
159
x
|
33.8
x
|
68.3
x
|
68.6
x
|
23.4
x
|
11.2
x
|
EV / Revenue
|
159
x
|
33.8
x
|
68.3
x
|
68.6
x
|
23.4
x
|
11.2
x
|
EV / EBITDA
|
-11.1
x
|
-2.07
x
|
-5.68
x
|
-6.75
x
|
-6.38
x
|
-4.33
x
|
EV / FCF
|
-7.7
x
|
-1.99
x
|
-5.96
x
|
-4.74
x
|
-5.89
x
|
-
|
FCF Yield
|
-13%
|
-50.3%
|
-16.8%
|
-21.1%
|
-17%
|
-
|
Price to Book
|
2.08
x
|
0.71
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
92,591
|
92,395
|
92,938
|
113,083
|
-
|
-
|
Reference price
2 |
8.200
|
2.100
|
4.200
|
4.270
|
4.270
|
4.270
|
Announcement Date
|
3/22/22
|
3/30/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
4.782
|
5.747
|
5.718
|
7.038
|
20.66
|
42.94
|
EBITDA
1 |
-
|
-68.58
|
-93.71
|
-68.76
|
-71.5
|
-75.65
|
-111.6
|
EBIT
1 |
-
|
-75.24
|
-106.8
|
-94.18
|
-85.59
|
-85.49
|
-78.01
|
Operating Margin
|
-
|
-1,573.36%
|
-1,857.49%
|
-1,647.08%
|
-1,216.05%
|
-413.86%
|
-181.67%
|
Earnings before Tax (EBT)
1 |
-
|
-109.9
|
-105.4
|
-110.5
|
-80.97
|
-82.06
|
-76.23
|
Net income
1 |
-14.35
|
-103.2
|
-104.9
|
-110.6
|
-84.98
|
-84.55
|
-76.23
|
Net margin
|
-
|
-2,159.01%
|
-1,825.37%
|
-1,933.65%
|
-1,207.42%
|
-409.27%
|
-177.53%
|
EPS
2 |
-10.55
|
-2.080
|
-1.150
|
-1.200
|
-0.8260
|
-0.7100
|
-0.5133
|
Free Cash Flow
1 |
-
|
-98.64
|
-97.51
|
-65.5
|
-101.8
|
-82
|
-
|
FCF margin
|
-
|
-2,062.84%
|
-1,696.78%
|
-1,145.44%
|
-1,446.33%
|
-396.94%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/6/21
|
3/22/22
|
3/30/23
|
3/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.452
|
0.819
|
1.002
|
2.369
|
1.557
|
1.269
|
3.367
|
0.744
|
0.338
|
0.898
|
2.315
|
1.823
|
1.981
|
6.8
|
8.15
|
EBITDA
1 |
-23.5
|
-25.9
|
-25.75
|
-24.56
|
-17.51
|
-18.33
|
-15.11
|
-17.25
|
-17.77
|
-
|
-17.3
|
-16.8
|
-17.3
|
-19
|
-20.6
|
EBIT
1 |
-26.26
|
-28.8
|
-28.89
|
-27.97
|
-21.09
|
-24.48
|
-21.65
|
-23.3
|
-24.74
|
-23.5
|
-20.55
|
-21.22
|
-20.48
|
-22.2
|
-26.5
|
Operating Margin
|
-1,808.26%
|
-3,516.85%
|
-2,882.93%
|
-1,180.54%
|
-1,354.72%
|
-1,929.47%
|
-643.09%
|
-3,132.12%
|
-7,319.23%
|
-2,616.7%
|
-888.02%
|
-1,164.29%
|
-1,033.62%
|
-326.47%
|
-325.15%
|
Earnings before Tax (EBT)
1 |
-26.27
|
-28.87
|
-28.95
|
-27.57
|
-19.97
|
-23.35
|
-41.66
|
-21.96
|
-23.5
|
-21.96
|
-19.45
|
-20.7
|
-19.33
|
-22.2
|
-26.5
|
Net income
1 |
-25.17
|
-29.49
|
-28.68
|
-27.26
|
-19.47
|
-23.36
|
-41.67
|
-21.99
|
-23.54
|
-21.98
|
-20.93
|
-21.6
|
-20.82
|
-22.2
|
-26.5
|
Net margin
|
-1,733.2%
|
-3,601.22%
|
-2,862.28%
|
-1,150.65%
|
-1,250.55%
|
-1,840.43%
|
-1,237.66%
|
-2,956.18%
|
-6,965.98%
|
-2,447.1%
|
-904.41%
|
-1,185.01%
|
-1,050.91%
|
-326.47%
|
-325.15%
|
EPS
2 |
-0.2800
|
-0.3300
|
-0.3200
|
-0.3000
|
-0.2100
|
-0.2600
|
-0.4500
|
-0.2400
|
-0.2500
|
-0.2200
|
-0.2000
|
-0.2020
|
-0.2040
|
-0.1200
|
-0.1300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/22/22
|
5/11/22
|
8/11/22
|
11/9/22
|
3/30/23
|
5/15/23
|
8/14/23
|
11/14/23
|
3/21/24
|
5/14/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
243
|
156
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-98.6
|
-97.5
|
-65.5
|
-102
|
-82
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-74.6%
|
-32.8%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-40.1%
|
-28.1%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
257.4
|
373.6
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
3.950
|
2.970
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-1.220
|
-0.9000
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
38
|
16.2
|
0.86
|
0.9
|
1
|
1
|
Capex / Sales
|
-
|
795.63%
|
281.45%
|
15.04%
|
12.79%
|
4.84%
|
2.33%
|
Announcement Date
|
5/6/21
|
3/22/22
|
3/30/23
|
3/21/24
|
-
|
-
|
-
|
Last Close Price
4.27
USD Average target price
8.628
USD Spread / Average Target +102.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.67% | 483M | | +54.05% | 58.71B | | -2.02% | 41.31B | | +36.67% | 39.2B | | -10.22% | 27.4B | | +13.42% | 26.55B | | -21.60% | 18.98B | | +2.89% | 12.51B | | +22.40% | 11.94B | | +27.49% | 12.08B |
Other Biotechnology & Medical Research
|